Skip to Content

RE-SPECT ESUS

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Emoblic Stroke of Undetermined Source (RE-SPECT ESUS)

Objective

You are being asked to participate in this research study because you have a condition called embolic stroke of undetermined source (ESUS), a type of ischemic stroke. An ischemic stroke occurs when an artery supplying blood to the brain becomes blocked. For most ischemic strokes, tests can be done to determine the cause of the blockage (for example, a blood clot). However, there is one type of ischemic stroke, where, despite testing, the origin of the blood clot causing the blockage is not identifiable. This condition has recently been named "embolic stroke of undetermined source" (ESUS). Subjects who experience a stroke due to a clot are at risk for another stroke. The majority of these subjects require lifelong treatment with a blood thinning medication to reduce the risk of another stroke.

The purpose of this study is to test the safety and effectiveness of the anticoagulant dabigatran etexilate taken twice daily compared to aspirin [acetylsalicylic acid (Acetylsalicylsaure 100 mg HEXAL®)] which is taken once daily for the prevention of stroke recurrence in subjects with ESUS.

If you would like to learn more about this trial, please follow the link below or contact Tina Fortney, RN, CCRC at 425-688-5407 or tina.fortney@overlakehospital.org.

Learn more about Overlake Medical Clinics Neurosurgery

 

Principal Investigator(s)
Abhineet Chowdhary, MD

Clinical Trial Categories

  • Neuroscience
Sponsor(s)
Boehringer Ingelheim Pharmaceuticals, Inc.
Contact
Research Study Staff at 425-688-5407

Location

  • Overlake Medical Center
    1035 116th Ave. NE
    Bellevue, WA 98004
    Main: 425-688-5000